Bone marrow transplantation for non-Hodgkin's lymphoma: A review

American Journal of the Medical Sciences

Volumn 313, Issue 4, 1997, Pages 228-235

  Salzman, Donna E ^a   Briggs, Adrienne D ^b   Vaughan, William P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE;

BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; NONHODGKIN LYMPHOMA; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030909886     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199704000-00006     Document Type: Review

References (32)

1. Philip T, Armitage JO, Spitzer G, Cauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Eng J Med. 1987;316:1493-8.
2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Eng J Med. 1995;333:1540-45.
3. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:583-95.
4. Sweetenham JW, Liberti G, Pearce R, Taghipour G, Santini G, Goldstone AH. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation. J Clin One. 1994;12:1358-65.
5. Vose JM, Peterson C, Bierman PJ, Weisenburger DD, Linder J, Harrington D, et al. (Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphoma. Blood. 1990;76:424-431.
6. Conde E, Sierra J, Iriondo A, Domingo A, Garcia Larana J, Marin J, et al. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO. Bone Marrow Transplant 1994;14:279-86.
7. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol. 1994;12:2543-51
8. Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, et al. High-dose carmustine, etoposide, and cisplatin and autoldgous bone marrow transplantation (or relapsed and refractory lymphoma. J Clin Oncol. 1992;10:1682-89.
9. Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cispiatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study. J Clin Oncol. 1996;14:534-42.
10. Sweetenham JW, Pearce R, Philip T, Proctor SJ, Mandelli F, Colombat P et al. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1994;14:981-87.
11. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL et al. One hundred autotransplants for relapsed or refractory Hodgkin's Disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol. 1993;11:2351-61.
12. Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll DP, et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol. 1996;14:586-92.
13. Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. For the European Group for Blood and Marrow Transplantation Lymphoma Working Party. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Bone Marrow Transplantation. J Clin Oncol. 1996;14:2465-72.
14. Colombat Ph, Donadio D, Fouillard L, Milpied N, Tilly H, Pico J, et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant. 1994;13:157-62.
15. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood. 1995;86:3257-62.
16. Fouillard L, Gorin NC, Laporte JPh, Douay L, Lopez M, Isnard F, et al. Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin's lymphoma. Eur J Haematol. 1991;46:279-84.
17. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. Expression of bcl-2 and bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest. 1987;80:1512-15.
18. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334-336.
19. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood. 1993;81:3449-57.
20. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro Jr J, Anderson WF, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet. 1993;341:85-6.
21. McCann JC, Kanteti E, Shilepsky B, Miller KB, Sweet M, Schenkein DP. High degree of occult tumor contamina- tion in bone marrow and peripheral blood stern cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biology of Blood Marrow Transplant. 1996;2:37-43.
22. Sharp JG, Kessinger A, Mann S, Crousc DA, Armitage JO, Bierman P, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol. 1996;14:214-19.
23. Rohatiner AZS, Johnson PWM, Price CGA, Arnott SJ, Amess JAL, Norton AJ, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12:1177-84.
24. Gorin N-C, Lopez M, Laporte J-P, Quittet P, Lesage S, Lemoine F, et al. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood. 1995;85:1647-54.
25. Zeudek M, Sana I, Salzman D, Tami JA. Depletion of lymphoma cells from bone marrow: use of sequential positive and negative immunoselection. Third International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation. San Diego, CA, March 16-18, 1995.
26. Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann, Colombat P, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol. 1996;14:2454-64.
27. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649-53.
28. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum L, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;84:1050-55.
29. van Besien KW, Khaouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol. 1995;13:1096-1102.
30. Briggs AD, Vaughan WP. Preparative regimens for autologous hematopoietic stem cell transplantation. Annals of One. In press.
31. Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol. 1995;13:596-602.
32. Mendoza E, Territo M, Schiller G, Lill M, Kumkel L, Wolin M. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphonia. Bone Marrow Transplant. 1995;15:299-303.